Pfizer Inc. (NYSE:PFE) Shares Purchased by Pittenger & Anderson Inc.

Pittenger & Anderson Inc. raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 13.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,001 shares of the biopharmaceutical company's stock after acquiring an additional 13,481 shares during the period. Pittenger & Anderson Inc.'s holdings in Pfizer were worth $2,939,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. V2 Financial group LLC boosted its holdings in Pfizer by 8.2% in the first quarter. V2 Financial group LLC now owns 32,114 shares of the biopharmaceutical company's stock worth $814,000 after acquiring an additional 2,443 shares in the last quarter. Fulton Breakefield Broenniman LLC lifted its stake in shares of Pfizer by 15.0% in the 1st quarter. Fulton Breakefield Broenniman LLC now owns 10,339 shares of the biopharmaceutical company's stock valued at $262,000 after purchasing an additional 1,350 shares during the last quarter. Stephens Inc. AR lifted its stake in Pfizer by 4.8% during the 1st quarter. Stephens Inc. AR now owns 363,368 shares of the biopharmaceutical company's stock worth $9,208,000 after acquiring an additional 16,489 shares in the last quarter. Schechter Investment Advisors LLC lifted its stake in Pfizer by 108.4% during the 1st quarter. Schechter Investment Advisors LLC now owns 17,456 shares of the biopharmaceutical company's stock worth $442,000 after acquiring an additional 9,079 shares in the last quarter. Finally, FDx Advisors Inc. raised its position in Pfizer by 9.2% in the 1st quarter. FDx Advisors Inc. now owns 9,288 shares of the biopharmaceutical company's stock valued at $235,000 after purchasing an additional 783 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Leerink Partners dropped their target price on Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Berenberg Bank reduced their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. The Goldman Sachs Group upped their price target on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Finally, Bank of America increased their price target on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $28.55.

Pfizer Stock Performance

Shares of PFE stock traded down $0.02 during trading on Wednesday, reaching $24.59. 44,174,346 shares of the company's stock traded hands, compared to its average volume of 41,947,842. The firm's 50-day moving average is $23.95 and its 200 day moving average is $24.77. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $139.79 billion, a P/E ratio of 17.82, a PEG ratio of 0.90 and a beta of 0.58. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.82 earnings per share. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.00%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.